Ironwood Lifts 2026 Outlook on Robust Q2 LINZESS Sales and Pipeline Progress with Apraglutide
IRWD has more than doubled off its 52-week low of $0.75.
Summary
Ironwood raised full-year 2026 guidance after Q2 LINZESS sales grew 14% to $282 million, repaid $200 million in convertible notes, and started a pivotal Phase 3 trial for apraglutide.
Key Events · Earnings and Guidance · IRWD
-
Raised Full-Year 2026 Guidance
LINZESS U.S. net sales guidance raised to $1.15–$1.20 billion (>30% YoY growth); total revenue guidance raised to $460–$485 million; adjusted EBITDA guidance raised to >$310 million.
-
Strong Q2 LINZESS Performance
Q2 LINZESS U.S. net sales of $282 million, up 14% YoY, driven by 4% demand growth and improved net price. Commercial margin expanded to 78% from 69%.
-
Q2 Financial Results
Total revenue of $113 million, GAAP net income of $51 million ($0.31 per share), and adjusted EBITDA of $83 million. Cash from operations was $58.3 million.
-
Debt Reduction
Repaid $200 million convertible senior notes at maturity using cash on hand, reducing leverage. Revolving credit facility balance remains $385 million.
Analysis · IRWD · Life Sciences
A beat-and-raise quarter underscores Ironwood's momentum: Q2 LINZESS U.S. net sales climbed 14% to $282 million, propelling total revenue to $113 million and GAAP net income to $51 million. Reflecting improved net price and mid-single-digit demand growth, management raised full-year LINZESS sales guidance to $1.15–$1.20 billion (up from $1.125–$1.175 billion) and total revenue to $460–$485 million. The balance sheet strengthened further as the company repaid its $200 million convertible notes with cash on hand. Meanwhile, the initiation of the confirmatory Phase 3 STARS-2 trial for apraglutide in short bowel syndrome marks a key pipeline catalyst. Together, the upwardly revised financials, debt reduction, and pipeline advancement materially enhance the investment thesis.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 35.7% of the 1024 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IRWD was trading at $4.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $683.1M. The 52-week trading range was $0.75 to $5.78. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.